Literature DB >> 2018530

Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase.

K E Dickinson1, A A Tymiak, R B Cohen, E C Liu, M L Webb, A Hedberg.   

Abstract

We have investigated the possible presence of endothelin-metabolizing neutral endopeptidase (NEP, EC 3.4.24.11) on A10 cell membranes using [125I]-ET-1 binding and direct measurements of NEP. NEP activity of A10 cell membranes has been compared to that of solubilized rat kidney brush border membranes (KNEP). Specific [125I]-ET-1 (50 pM) binding (defined with 100 nM ET-1) to A10 cell membranes was increased in a concentration dependent manner by the selective NEP inhibitors thiorphan, phosphoramidon, and SQ 28,603 [(+/-)-N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine] with EC50 values of 9.4, 28.4, and 5.7 nM respectively. At equilibrium (150 min), 70% more specific binding was apparent in the presence of these inhibitors. Phosphoramidon (2 microM) did not alter Bmax values, but it decreased the apparent KD for [125I] ET-1 from 63 (+/- 3) to 27 (+/- 2) pM. Thiorphan, phosphoramidon, and SQ 28,603 inhibited A10 cell NEP activity with IC50 values of 5.3, 36.5, and 6.0 nM respectively, which was similar to values obtained with KNEP (3.6, 22.6, and 3.5 nM). ET-1 inhibited A10 cell NEP, and KNEP with IC50 values of 30 and 21.3 microM respectively. The order of inhibitory potencies: ET-3 greater than ET-1 = ET-2 greater than or equal to sarafotoxin-6b was similar for both systems. These data suggest A10 cell membranes contain a NEP which has similar characteristics to NEP 24.11, and which actively metabolizes [125I]-ET-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018530     DOI: 10.1016/0006-291x(91)90941-y

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: possible mechanism for ischemia-induced acute renal failure in rats?

Authors:  P Nambi; M Pullen; H L Wu; U Prabhakar; L Hersh; M Gellai
Journal:  Mol Cell Biochem       Date:  1999-07       Impact factor: 3.396

2.  Endothelin receptors in rat pituitary gland.

Authors:  S Shibata; A Himeno; K Shigematsu; K Tsutsumi; Y Sakurai-Yamashita; K Yamashita
Journal:  Cell Mol Neurobiol       Date:  1997-02       Impact factor: 5.046

3.  Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11.

Authors:  Z A Abassi; E Golomb; R Bridenbaugh; H R Keiser
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

4.  Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

5.  The two-step conversion of big endothelin 1 to endothelin 1 and degradation of endothelin 1 by subcellular fractions from human polymorphonuclear leukocytes.

Authors:  S Kaw; M Hecker; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

6.  Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

Authors:  John Gatfield; Celia Mueller Grandjean; Thomas Sasse; Martine Clozel; Oliver Nayler
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.